Flowcore Upgrade: Amnis ImageStream Flow Cytometer
Flowcore Upgrade: Amnis ImageStream Flow Cytometer
批准号:
7794705
负责人:
Luis J Montaner
金额:
$36.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2011-08-31
关键词:
Antigen-Presenting CellsApoptosisApoptoticArtsAutoimmunityCancer BiologyCellsCommunicable DiseasesDataData AnalysesEventFlow CytometryFluorescence MicroscopyFundingGenetic TranscriptionImageImage AnalysisImmuneIndividualLocationMeasurementMicroscopyMolecularMorphologyMovementNuclearNuclear TranslocationPopulationQuantitative MicroscopyRecruitment ActivityResearchResearch PersonnelSamplingSignal TransductionSignaling MoleculeSlideSpeedSpottingsSuspension substanceSuspensionsSynapsesSystemT-LymphocyteTechniquesTechnologyTimeUnited States National Institutes of HealthVisualgene therapyinstrumentinstrumentationnew technologypublic health relevancetoolvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This is a proposal to acquire an Amnis ImageStream high speed imaging flow cytometer as an additional, new technology for NIH-sponsored research in Wistar's Flow Cytometry Facility. The ImageStream system combines the visual power of microscopy, the quantitative ability of image analysis, and the statistical rigor of flow cytometry in a single platform to create new experimental capabilities. In addition this technology would provide an adjunct tool to have when traditional flow cytometry and microscopy results are either unclear or unexpected. The advantages of the ImageStream as compared to traditional flow cytometry are associated with morphology, providing much of the fluorescent information of a flow cytometer (though at a lower cell throughput rate than flow), but at the same time identifying the location of the signal, which enables the study or tracking of signaling events or the movement of events that happen either on, within or between cells. Also, the ability to associate a spot with its image or images gives the ability to be sure that what you think is a rare event is truly a cell and not a piece of debris. The advantages of the ImageStream as compared to traditional fluorescence microscopy include the ability to look at non-adherent cells in suspension, important because forcing these cells to stick to slides and immobilize them could have strong negative effects on the cells. In addition, the ability to acquire brightfield, darkfield and 4 fluorescent channel images simultaneously on tens to hundreds of cells per second allows for true statistically valid data analysis. Plus, one can quantify signal on thousands of cells while still obtaining individual cell data. Normal microscopy techniques look at only a few hundred cells in a population, making rare event analysis difficult and impractical, if not impossible to do. NIH-funded investigators propose to apply this technology towards: Nuclear Translocation - Quantitative per-cell measurement of nuclear translocation of signaling molecules on large samples; Internalization - Measurement of apoptosis by nuclear morphology change and expression of apoptotic markers; Molecular Co-localization - Quantitative per- cell measurement of the co-association of one or more molecules within or on a cell; Immune Synapse - Quantitative identification of conjugates with molecules recruited to the point of contact between two interacting cells, typically a T cell and an antigen presenting cell (APC). Taken together, the proposed instrumentation usage as justified in this proposal will advance NIH funded research in cancer biology, infectious disease, autoimmunity and vaccine development.
PUBLIC HEALTH RELEVANCE: The requested Amnis ImageStream Analyzer instrument will enable Wistar to extend access of state-of-the-art cell analysis in support of multiple NIH-funded projects focused on cellular analysis of transcription, autoimmunity, infectious disease, cancer biology, gene therapy, and vaccine development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Purchase of MVE Fusion Self-Sustaining Cryogenic Freezers
-
批准号:10533525
-
项目类别:
-
资助金额:$11.05万
-
财政年份:2022
-
负责人:Luis J Montaner
-
依托单位:
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
-
批准号:10469617
-
项目类别:
-
资助金额:$583.97万
-
财政年份:2021
-
负责人:Luis J Montaner
-
依托单位:
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
-
批准号:10609926
-
项目类别:
-
资助金额:$578.07万
-
财政年份:2021
-
负责人:Luis J Montaner
-
依托单位:
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
-
批准号:10313067
-
项目类别:
-
资助金额:$610.0万
-
财政年份:2021
-
负责人:Luis J Montaner
-
依托单位:
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers
-
批准号:10291661
-
项目类别:
-
资助金额:$157.16万
-
财政年份:2021
-
负责人:Luis J Montaner
-
依托单位:
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder
-
批准号:10621847
-
项目类别:
-
资助金额:$76.62万
-
财政年份:2019
-
负责人:Luis J Montaner
-
依托单位:
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder
-
批准号:10381326
-
项目类别:
-
资助金额:$15.69万
-
财政年份:2019
-
负责人:Luis J Montaner
-
依托单位:
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder
-
批准号:10406244
-
项目类别:
-
资助金额:$92.56万
-
财政年份:2019
-
负责人:Luis J Montaner
-
依托单位:
Towards Eradication: Reducing Proviral HIV DNA with Interferon-a Immunotherapy
-
批准号:8671884
-
项目类别:
-
资助金额:$170.84万
-
财政年份:2014
-
负责人:Luis J Montaner
-
依托单位:
Purchase a Beckman Coulter MoFlo Astrios Flow Cytometer
-
批准号:8639790
-
项目类别:
-
资助金额:$59.49万
-
财政年份:2014
-
负责人:Luis J Montaner
-
依托单位:
Towards Eradication: Reducing Proviral HIV DNA with Interferon-α Immunotherapy
-
批准号:8988529
-
项目类别:
-
资助金额:$183.73万
-
财政年份:2014
-
负责人:Luis J Montaner
-
依托单位:
Pediatric Immune Correlates of Early Anti-HIV Therapy
-
批准号:8049900
-
项目类别:
-
资助金额:$51.5万
-
财政年份:2010
-
负责人:Luis J Montaner
-
依托单位:
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users
-
批准号:8601696
-
项目类别:
-
资助金额:$70.1万
-
财政年份:2010
-
负责人:Luis J Montaner
-
依托单位:
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users
-
批准号:8420534
-
项目类别:
-
资助金额:$67.83万
-
财政年份:2010
-
负责人:Luis J Montaner
-
依托单位:
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users
-
批准号:8213606
-
项目类别:
-
资助金额:$67.89万
-
财政年份:2010
-
负责人:Luis J Montaner
-
依托单位:
NK Cell Activation and Function in HIV-1 Exposed Uninfected IV Drug Users
-
批准号:8044828
-
项目类别:
-
资助金额:$66.55万
-
财政年份:2010
-
负责人:Luis J Montaner
-
依托单位:
Flow Cytometry
-
批准号:7945002
-
项目类别:
-
资助金额:$15.8万
-
财政年份:2009
-
负责人:Luis J Montaner
-
依托单位:
Innate Effector Function and HIV-1 Control
-
批准号:7620589
-
项目类别:
-
资助金额:$26.24万
-
财政年份:2009
-
负责人:Luis J Montaner
-
依托单位:
Innate Effector Function and HIV-1 Control
-
批准号:7847484
-
项目类别:
-
资助金额:$20.5万
-
财政年份:2009
-
负责人:Luis J Montaner
-
依托单位:
Tri-Society Meeting of International Cytokine Society (ICS), International Societ
-
批准号:7808663
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2009
-
负责人:Luis J Montaner
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: